XWPharma: XWPharma Completes $40 Million Round for Neurobiology Candidates

XWPharma of Wuhan completed a $40 million Series C financing to develop its portfolio of novel neurobiology candidates. XW, which also has operations in Redwood City, California, was previously known as XW Laboratories. In addition, the company announced that Leonard Blum, an industry veteran, will become President and CEO of XW, and will spearhead increased emphasis on US development. The C round was led by Panacea Venture. In its two previous rounds, XW raised $23 million in venture capital. More details....Share this with colleagues: